You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
TATA健康(01255.HK)投資新興肝病治療產品公司 涉資近2,000萬歐元
阿思達克 06-30 10:40
TATA健康(01255.HK)公佈,旗下附屬商贏計劃認購Promethera Therapeutics 37.61%股權及貸款,總代價爲1,999.47萬歐元;分爲總金額1,399.5萬歐元的股份認購及總金額600萬歐元的貸款。Promethera Therapeutics爲比利時註冊成立的公司,從事諸如探索、研究、開發、製造及商業化HepaStem及H2Stem以及以創新方式治療肝臟疾病的新興治療產品的業務活動,使用來自健康人體肝臟的異體幹細胞。

同時公司與Promethera Biosciences及Promethera Therapeutics訂立購股協議,據此商贏將收購合營公司已發行股本總數的40%權益,代價爲1歐元。

公司認爲,Promethera Therapeutics以及其前身Promethera Biosciences爲肝臟細胞治療領域的先驅,於末期肝病治療方面處於領導地位,其主要產品HepaStem處於2B期臨牀研究。由於肝病在中國十分普遍,且細胞及再生醫學行業日益成熟並獲得國家支持,公司投資Promethera Therapeutics及收購合營公司40%股權,公司及Promethera Therapeutics均有利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account